Sinigrin is a glucosinolate that has been found inBrassicaand has diverse biological activities.^1,2,3It inhibits NOD-like receptor protein 3 (NLRP3) inflammasome activation in ATP-stimulated, LPS-primed RAW 264.7 cells in a concentration-dependent manner.¹Sinigrin (1-100 µg/ml) reduces LPS-induced production of nitric oxide (NO) and prostaglandin E₂, as well as NF-κB activation, in RAW 264.7 cells. It induces cell cycle arrest at the G₀/G₁phase in HepG2 hepatocellular carcinoma cells when used at concentrations of 0.1 and 0.5 mM.²Sinigrin (10 and 20 mg/kg) reduces increases in renal glomerular basement membrane thickness, as well as increases in systolic and diastolic blood pressure, in a rat model of hypertension induced by angiotensin II.³

1.Lee, H.-W., Lee, C.G., Rhee, D.-K., et al.Sinigrin inhibits production of inflammatory mediators by suppressing NF-κB/MAPK pathways or NLRP3 inflammasome activation in macrophagesInt. Immunopharmacol.45163-173(2017) 2.Jie, M., Cheung, W.M., Yu, V., et al.Anti-proliferative activities of sinigrin on carcinogen-induced hepatotoxicity in ratsPLoS One9(10)e110145(2014) 3.Cong, C., Yuan, X., Hu, Y., et al.Sinigrin attenuates angiotensin II?induced kidney injury by inactivating nuclear factor?κB and extracellular signal?regulated kinase signaling in vivo and in vitroInt. J. Mol. Med.48(2)161(2021)